News
LEXXW
0.0012
0.00%
0.00
Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate
Benzinga · 1d ago
Lexaria FY26 nine-month net loss narrows to US$ 5.04 million; revenue drops to US$ 20,000
PUBT · 1d ago
Weekly Report: what happened at LEXX last week (0706-0710)?
Weekly Report · 1d ago
New Fed Boss Speaks Next Week
Barchart · 2d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 6d ago
Lexaria reports ‘positive’ meetings with potential partners at BIO convention
TipRanks · 07/06 13:25
Weekly Report: what happened at LEXX last week (0629-0703)?
Weekly Report · 07/06 09:08
Lexaria Updates Business Development
Barchart · 07/06 08:10
Weekly Report: what happened at LEXX last week (0622-0626)?
Weekly Report · 06/29 09:07
Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing
TipRanks · 06/25 13:15
Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy
Benzinga · 06/25 13:14
Lexaria begins dosing in five-week oral semaglutide study versus Novo’s Wegovy tablets
PUBT · 06/25 13:10
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
Barchart · 06/25 08:10
Lexaria Bioscience begins dosing in animal study GLP-1-A26-1
TipRanks · 06/23 15:26
Lexaria receives Australian patent grant for hypertension treatment compositions
PUBT · 06/23 13:25
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
Barchart · 06/23 08:25
Weekly Report: what happened at LEXX last week (0615-0619)?
Weekly Report · 06/22 09:08
Lexaria Bioscience provides update on GLP-1 oral pill market
TipRanks · 06/17 13:42
Lexaria says oral GLP-1 drugs expand market as sector sales forecasts climb to USD 139 billion by 2030
PUBT · 06/17 13:25
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 06/15 21:05
More
Webull provides a variety of real-time LEXXW stock news. You can receive the latest news about Lexaria Bioscien through multiple platforms. This information may help you make smarter investment decisions.
About LEXXW
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.